Kornimate/medical-research-clean huggingface dataset:
bagel - bariatric patients in primary care: post-operative nutrition and lifestyle management

Conditions: Bariatric Surgery Candidate; Malnutrition

Summary: there is a growing number of patients undergoing bariatric surgery requiring lifelong follow-up. bagel (bariatric patients in primary care: post-operative nutrition and lifestyle management) is a survey to evaluate a newly developed structured disease management program including nutrition and lifestyle management in primary care.

during last decades the prevalence of obesity is growing. therefore, the number of bariatric procedures are also increasing. frequent complications after surgery are nutritional deficiencies (e.g. vitamins, minerals, protein) which require mandatory long-term follow-up. so far adequate follow-up programs are only provided in specialized bariatric centers like in the outpatient clinic for obesity at the general hospital of vienna. these programs are focusing on prevention and premature identification of deficiencies. rising numbers of bariatric-surgical procedures pose a challenge for bariatric centres because of the accumulating numbers of bariatric patients requesting follow-up at least once a year. to provide full coverage an appropriate possibility would be to transfer follow up to non-specialised facilities including general practitioners and family doctors using a so called "pass" providing practical treatment recommendations (necessary follow-up appointments, laboratory blood tests, questions regarding nutrition and lifestyle behavior). to our best knowledge such a structured post-bariatric care management program in primary care does not exist by now. the aim of this study is therefore the evaluation of such a pass.

Eligibility criteria:
inclusion criteria: * older than 18 years and each sex, * bariatric-surgical treatment - in particular omega loop gastric bypass, roux-en-y-gastric bypass - and sleeve gastrectomy at the department of surgery general hospital vienna, * operation date maximum 21 months before study beginning, exclusion criteria: * pregnancy (a possible existing pregnancy is excluded by questioning) * nursing mothers * not german speaking patients

Keywords: bariatric surgery lifelong follow-up primary care obesity health care study
a study of the effect of pf-04802540 on sleep measures

Conditions: Healthy

Summary: the purpose of this study is to determine if pf-04802540 decreases rem sleep.


Eligibility criteria:
inclusion criteria: * healthy male and/or female (nonchildbearing potential) subjects between the ages of 18 and 55 years, inclusive * body mass index (bmi) between 18 to 32 kg/m2, inclusive, and a total body weight \>45 kg (99 lbs) * non-users of nicotine exclusion criteria: * evidence or history of clinically significant medical illness * a history of seizures, including childhood febrile seizures * any condition possibly affecting drug absorption

Keywords: pf-04802540, polysomnography, rem, cross over
effect of combined fatty acid supplementation and eccentric exercise training on exercise performance

Conditions: Exercise-induced Inflammation

Summary: the aim of the study is to determine whether fish oil (specifically omega-3 long chain polyunsaturated fatty acids \[epa-dha\]) supplementation can enhance eccentric resistance exercise performance when combined with a resistance exercise training study. the investigators aim to establish the potential mechanisms that might mediate performance changes at a cellular level.


Eligibility criteria:
inclusion criteria: * males * healthy exclusion criteria: * resistance exercise training within the past 6 months * vitamin or fish oil supplementation over the past 6 months * habitual use of anti-inflammatory drugs * history of heart disease * history of coagulation/bleeding disorder * history of metabolic disease * serious allergy * known to have blood-borne virus * females (due to differences in cell membrane incorporation of omega-3 between the sexes and the testing schedule being unable to fit in with menstrual cycle, altering the blood markers that are being measured) * currently no symptoms of general illness
bioresorbable membrane to reduce postoperative small bowel obstruction

Conditions: Gastric Cancer

Summary: to assess whether the use of seprafilm reduces the rate of small bowel obstruction in patients who underwent surgery for gastric cancer.

patients with gastric cancer who were scheduled to undergo gastrectomy were randomly assigned to a sodium hyaluronate-based bioresorbable membrane (seprafilm) group or to a control group. before closing the abdominal incision, two sheets of seprafilm membrane were applied to the surface of the small intestine under the middle abdominal wound in the seprafilm group. the primary end point was the incidence of bowel obstruction. secondary end points were intraoperative and postoperative morbidity and mortality.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of gastric cancer * operable exclusion criteria: * withdrew consent * pregnant * ascites * distant metastasis * liver dysfunction (serum total bilirubin \>2.0 mg/dl) * renal failure (serum creatinine \>1.5 mg/dl) * a past history of small bowel obstruction.
the effects of short message notifications on middle-aged diabetic patients

Conditions: Type2 Diabetes Mellitus

Summary: the objective of our study was to assess awareness-raising of medication adherence (ma), physical activity (pa), fasting blood glucose (fbg), and glycated hemoglobin a (hba1c) values by providing information on diabetes via short message (sms) technology.

the study investigates t2dm patients who have not had surgery or cardiac event in the last 3 months, between the ages of 40 and 64 years, with t2dm diagnosis between the last 1 and 10 years and oral antidiabetic therapy for at least 1 the study design is a single-blinded randomized, controlled study, and was conducted in the diabetes polyclinic of the istanbul university medical faculty hospital. patients randomly assigned to the intervention group, in addition to traditional treatment received three to four informative sms messages per week during the 6-month period, while the control group was followed in accordance with the traditional treatment schedule.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of type 2 diabetes mellitus (t2dm) between the last 1 and 10 years * being aged between 40 and 64 years old, * is treated for a minimum of 1 year with at least one oral antidiabetic drug. exclusion criteria: * clinical diagnosis of t2dm for less than 1 year or more than 10 years. * those who have had surgery or a cardiac event in the last 3 months or during the investigation. * those under 40 and over 64 years of age. * patients with t2dm that have not been treated with oral antidiabetic medication. * volunteers who once did not participate in the control examinations in both groups were excluded from the evaluation.

Keywords: diabetes mellitus public health
how to improve diagnosis in infective endocarditis

Conditions: Endocarditis, Bacterial

Summary: the purpose is to exam prospective if simple clinical information in combination with a normal s-procalcitonin are sufficient for exclusion of infective endocarditis (ie).

despite progress in surgical and medical treatment, infective endocarditis is still associated with high morbidity and mortality. the variable clinical presentation of ie makes the diagnosis a clinical challenge. procalcitonin is a precursor from the hormone calcitonin and also a marker of systemic bacterial infections. the purpose of this study is: * to investigate the diagnostic value of serum procalcitonin (pct), c-reactive protein (crp) and sedimentation rate (sr) when ie is suspected. * to investigate if a retrospectively generated clinical model suitable for exclusion of ie can be confirmed prospectively.

Eligibility criteria:
inclusion criteria: * patients \> or = 18 year with suspected or verified infective endocarditis * by word of mouth or in writing consent exclusion criteria: * incapacity
feasibility study of laser treatment of the crystalline lens to correct presbyopia

Conditions: Presbyopia; Cataract

Summary: the study will evaluate whether the lensar laser system can be used in the lens of the eye to increase the ability to read and/or see near objects

the objective of this study is to evaluate the feasibility of the lensar laser system to surgically intervene within the crystalline lens to improve vision by increasing amplitude of accommodation in patients having elected to undergo lens extraction and iol implantation

Eligibility criteria:
inclusion criteria: * subjects must sign and be given a copy of the written informed consent form. * subjects must have elected to undergo lens extraction and iol implantation to treat their ocular disorder then elect to have the lensar laser surgery as part of the procedure. * cataract should not exceed locs iii grade 2. * subjects must have best corrected distance visual acuity of 20/40 or better in the eye to be treated . * subjects must be ≥ 45 years and ≤ 60 years of age at time of subject eligibility visit. * subjects must be willing and able to return for scheduled follow up examinations for 6 months after cataract surgery or up to 3 years (at 6 month intervals) if no cataract surgery is performed. * subject must have central 7 mm of clear cornea without vascularization exclusion criteria: * subjects who are pregnant, lactating, or planning to become pregnant during the course of the study. * subjects who have undergone previous corneal or intraocular surgery in the eye to be treated. * subjects with a history, signs or symptoms of ocular disease or atypical finding which would be contraindicated under standard of care for cataract surgery. * diabetic or hypertensive subjects with clinical evidence of retinal pathology. * subjects with macular degenerative pathology. * subjects with a history of steroid-responsive rise in iop or uncontrolled glaucoma in either eye. * subjects with known lens/zonular instability such as, but not restricted to, marfan's syndrome, pseudoexfoliation syndrome, etc. * subjects with corneal disease or pathology that precludes applanation of the cornea or transmission of laser wavelength or distortion of laser light. * subjects who cannot attain ocular dilation adequate to allow laser treatment within the minimum range based on the laser procedure to be applied. * subjects with known sensitivity to planned study concomitant medications. * subjects using systemic medication that is known to reduce the amplitude of accommodation (such as medication for motion sickness containing hyoscine or other antimuscarinic drugs, anticholinergic drugs, anti-psychotic drugs, tricyclic antidepressants and other drugs acting on the central nervous system). * subjects participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation.

Keywords: accommodation presbyopia crystalline lens
deepview snapshot handheld (dv-h) comparison study

Conditions: Burns

Summary: his study is being done to collect pictures of burns using an investigational device called the spectral md deep view snapshot handheld (dv-h), similar to a camera. the data collected will be used to assess the performance of the dv-h device, and to determine the device's ability to differentiate healing versus non-healing burn tissue. this device, if approved, is expected to give caregivers a better understanding of what parts of burn wounds will likely not heal on their own and as a tool used by the military in the field. this current study involves the collection of images over the course of your clinical treatment and follow-up according to your routine standard of care. the device will not be used to diagnose or prescribe treatment for your burn


Eligibility criteria:
inclusion criteria: .age \>18 years and able to give informed consent or have a legally authorized representative (lar) able to do so; * life expectancy \> 6 months; * thermal burn mechanism (flame, scald, or contact); * the study burn(s) occurred less than 72 hours prior to the time of first imaging; * minimum burn wound size for patients is 0.5% tbsa per region * have 2 - 4 regions of their clinical burn(s) that meet the criteria for a study burn; and exclusion criteria: * patients will be excluded if any of the following conditions apply: * burn pattern distribution isolated to head, face, neck, hands, feet, genitalia, and/or joints; * subject has burns involving \> 50% total body surface area (tbsa); * sepsis at the time of enrollment determined by diagnosis made by principal investigator or sub-investigator; * immunosuppression/radiation/chemotherapy \< 3 months prior to enrollment; * concurrent use of investigational products with a known effect on the burn sites; and/or * any condition that in the opinion of the investigator may prevent compliance with the study requirements or compromise subject safety.
a study of the effects of oral prednisone in patients with rheumatoid arthritis (mk0000-088)

Conditions: Rheumatoid Arthritis

Summary: the study will compare the effects of prednisone vs placebo on synovial blood flow and overall das (disease activity score) in patients with rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * patient is willing to limit alcohol intake to 3 or less beverages per day * patient agrees to use only acetaminophen/paracetamol for breakthrough pain exclusion criteria: * patient has other inflammatory arthritis (e.g. lupus). patient has had major surgery or donated or lost 1 unit of blood in the last 4 weeks * patient has a history of drug or alcohol abuse in the last 2 years * patient has had a vaccine (with a live or attenuated virus) in the last two weeks
use of oxybutynin for treating hyperhidrosis: a placebo-control study

Conditions: Hyperhidrosis

Summary: video-assisted thoracic sympathectomy (vats) provides excellent resolution of palmar and axillary hyperhidrosis but is associated with compensatory hyperhidrosis. low doses of oxybutynin can be used to treat palmar hyperhidrosis with fewer side effects.

introduction: video-assisted thoracic sympathectomy (vats) provides excellent resolution of palmar and axillary hyperhidrosis but is associated with compensatory hyperhidrosis. low doses of oxybutynin can be used to treat palmar hyperhidrosis with fewer side effects. purpose: the objective of this study is to evaluate the effectiveness and patient satisfaction with the use of oxybutynin at low doses comparing to placebo for treating palmar hyperhidrosis. methods: this is a prospective, randomized and controlled study. from december 2010 to february 2011, 50 consecutive patients with palmar hyperhidrosis were treated with oxybutynin or placebo. data were collected from 50 patients, and 5 (10,0%) patients were lost to follow-up. during the first week, patients received 2.5 mg of oxybutynin once a day in the evening. from the 8th to the 42nd day, they received 2.5 mg twice a day, and from the 43rd day to the end of the 12th week, they received 5 mg twice a day. all of the patients underwent 2 evaluations: before and after (12 weeks) the oxybutynin treatment, using a clinical questionnaire; and a clinical protocol for quality of life (qol).

Eligibility criteria:
inclusion criteria: * adult patients with hyperhidrosis exclusion criteria: * glaucoma and pregnancy

Keywords: hyperhidrosis oxybutynin
hrqol in locally advanced thyroid carcinoma

Conditions: Thyroid Cancer; Tyrosine Kinase Inhibitor; Health Related Quality of Life

Summary: the purpose of this study was to explore the changes of health-related quality of life (hrqol) in patients with locally advanced thyroid cancer (latc) receiving tki drugs (anlotinib, lenvatinib, etc.).

surgical resection is the cornerstone of treatment for thyroid cancer. however, some patients present with locally advanced disease at the time of diagnosis, and they are not eligible for radical resection. another patients still had the risk of recurrence after surgery, endocrine therapy and iodine-131 treatment. tyrosine kinase inhibitors (tki) have been proved to be effective in thyroid cancer patients. however, it was still unclear whether tki drugs had influence on the hrqol of latc patients. the purpose of this study was to explore the changes of health-related quality of life (hrqol) in patients with locally advanced thyroid cancer (latc) receiving tki drugs (anlotinib, lenvatinib, etc.).participants enroll the study after informed consent, and quality of life will be assessed using quality of life questionnaires eortc qlq c30, and eortc thy 47 before surgery, and 1,3,6 and 12 months after treatment.

Eligibility criteria:
inclusion criteria: * patients age (18-70 year old) * diagnosis of locally advanced thyroid cancer * patient receiving tki drugs. exclusion criteria: * pregnancy or breastfeeding women; * history of other malignant diseases, unstable angina, myocardial infarction, cerebral infarction or cerebral hemorrhage within 6 months; (3) patients missing questionnaires greater than 3 times.

Keywords: hrqol thyroid cancer targeted therapy tyrosine kinase inhibitor
exploratory investigation on a novel catheter

Conditions: Bowel Dysfunction

Summary: an exploratory, pre-market, open, prospective, interventional, clinical investigation at a limited number of centers for proof of concept of a new catheter. in this proof of concept investigation, subjects experienced in using transanal irrigation (tai) with a balloon catheter will be using study catheters at two occasions to primarily study if the catheter will stay in place during the water instillation when performing tai. each subject will be followed during approximately one week, depending on the usual time between their tai.


Eligibility criteria:
inclusion criteria: 1. provision of informed consent. 2. female and male aged 18-80 years. 3. patients successfully treated by tai with navina smart system for at least 3 months and/or stable in therapy. 4. patients considered suitable to participate by investigator. 5. able to read, write and understand information given to them regarding the study. exclusion criteria: 1. involvement in the planning and conduct of the clinical investigation (applies to both wellspect healthcare staff and staff at the study site). 2. previous enrolment in the present clinical investigation. 3. simultaneous participation in another clinical investigation, or participation in a clinical investigation during the last month, that may interfere with the present clinical investigation. 4. severe non-compliance to clinical investigation plan as judged by the investigator and/or wellspect healthcare. 5. significant cardiovascular and/or other significant co-morbidities which could be negatively affected by the use of the investigational product. 6. known anal or colorectal stenosis. 7. active inflammatory bowel disease. 8. acute diverticulitis. 9. colorectal cancer. 10. ischemic colitis. 11. any anal or colorectal surgery within the previous 3 months. 12. anal, rectal and/or colonic endoscopic polypectomy within the previous 4 weeks. 13. any condition, as judged by the investigator, which might make follow-up or investigations inappropriate. 14. any patient that according to the declaration of helsinki is unsuitable for enrolment.
niv-nava vs niv-ps/pc in respiratory insufficiency

Conditions: Respiratory Insufficiency; Acute Respiratory Insufficiency

Summary: this study evaluates the difference between non invasive ventilation with neurally adjusted ventilatory assist (niv-nava) and conventional non invasive ventilation with pressure support (ps) or pressure control (pc). all the patients are ventilated in each mode for 4 hours. afterwards they will be subjected to a semi-structured interview where they will be asked to compare the two modes. the hypothesis is that niv-nava will correct patients power of hydrogen (ph), paco2 og pao2 more quickly than niv-ps and niv-nava is more comfortable for the patients.

neurally adjusted ventilatory assist (nava) is a ventilation mode where the diaphragm is controlling the amount of ventilatory assistance proportionally through a nasogastric tube containing electrodes which are sending the electrical activities of the diaphragm (eadi) to the ventilator. whereas conventional ventilation modes like pressure support or pressure control are dependent on the pressure drop or flow reversal to initiate assist delivered to the patient. this is last step of the signal chain leading to inhalation and is subject to disturbances such as intrinsic positive expiratory end pressure (peep), hyperinflation and leakage.

Eligibility criteria:
inclusion criteria: * patients admitted at the icu with acute respiratory insufficiency and therefore have hypoxia(pao2 \ 6.0 kpa). * patients, which according to the departments guidelines are required to treatment with niv exclusion criteria: * patients under years of 18. * patients without the possibility to give informed consent. * patients with neuromuscular or neurological disease. * patients with a verified or suspected head trauma. * patients with a acknowledged hiatus hernia. * patients with an active or suspected active upper gi bleeding. * patients which have previously been in the study. * patients with a suspected or verified acute coronary syndrome.

Keywords: hypoxia hypercapnia
efficacy of bio-k+ cl1285® prophylaxis in the prevention of traveler's diarrhea in adults

Conditions: Diarrhea

Summary: the purpose of this study is to determine the efficacy of bio-k+ cl1285 in reducing traveler's diarrhea.

determine efficacy of bio-k+ cl1285 in reducing traveler's diarrhea by comparing the incidence of diarrhea in travelers during their stay abroad and upon their return to canada following either bio-k+ cl-1285 or placebo prophylaxis.

Eligibility criteria:
inclusion criteria: * male or female subjects over 18 years of age traveling to mexico, central america, south america and caribbean islands as direct destinations or on cruises to the same destinations. * the trips last a minimum of 7 days and a maximum of 21 days. * women of child bearing capacity who are not pregnant at the moment of screening (pregnancy test done on-site) and agree to use an acceptable form of birth control for the duration of the study (e.g. condom, oral contraceptives, etc.) are allowed to participate. exclusion criteria: * active diarrhea; * pregnancy; breastfeeding * 3 diarrheic episodes within 24 hours in the 15 days preceding the date of the departure; * antibiotic treatment during the last 15 days or ongoing treatment at the time of departure; * consumption of fermented milk, yogourt or probiotics probiotics in the 15 days preceding the date of the departure; * immunosuppressed state or any health condition being susceptible to decompensate during the study (including malignant hemo-pathologies, aids, bone marrow transplant or organ transplant). * active radiotherapy or chemotherapy as cancer treatment * the administration of an etec/cholera vaccine or any other diarrhea vaccine in the three months prior to study initiation * an active, non-controlled intestinal disease; * ileostomy, jejunostomy or colostomy * concomitant participation in another clinical trial * mental or other conditions, or language barriers rendering the subject unable to understand the nature, scope, and possible consequences of the study or complete the self-administered questionnaires; * subject unlikely to comply with protocol, e.g., uncooperative attitude, and unlikelihood of completing the study, * allergies to any ingredients in the study product (active product or placebo) * current use of illicit drug and alcohol abuse

Keywords: bio-k+cl1285 probiotics traveler's diarrhea lactobacillus acidophilus lactobacillus casei